Nyheter m m

Cision

Camurus AB15 min. fördröjning

Förändring2.69% Senast72,50 SEK
Köp Sälj Läs mer
		

Camurus AB: Camurus Annual Report for 2018

17:33 Lund, Sweden - 15 April 2019 - Camurus (CAMX) today announces that the Annual Report for 2018 now is available at the companys website: www.camurus.com. About Camurus Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal drug delivery technologies and its extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com. For more information Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 fredrik.tiberg@camurus.com Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 ir@camurus.com ----------------------------------------------------------- https://news.cision.com/camurus-ab/r/camurus-annual-report-for-2018,c2789783 https://mb.cision.com/Main/13456/2789783/1026606.pdf © Cision
FooterBanner

Finansiella instrument kan både öka och minska i värde. Det finns en risk att du inte får tillbaka de pengar du investerar. Innan du investerar i en fond bör du läsa informationsbroschyren som finns hos fondbolaget och faktabladet som du hittar i orderläggningsfönstret samt på fondens produktsida på nordnet.se.